Document is current
Any future updates will be listed below
-
Authors
Zimmermann, Milan https://orcid.org/0000-0001-7066-7749
Schöls, Ludger
- License Information
-
More Information
Article History
Received: 8 July 2025
Accepted: 30 September 2025
First Online: 21 January 2026
Declarations
:
: The authors declare that they have no conflict of interest in relation to the manuscript.Dr. Milan Zimmermann has received a research grant from the University of Tuebingen (Clinician Scientist; Project-Nr. 481-0-0).Ludger Schöls received funding by the German Research council (DFG grant SCHO754/6 − 2), German Ministry of Health (BMG grant ZMVI1- 2520DAT94E to LeukoExpert), German Ministry of Education and Research (BMBF grant 01GM1905A to Treat HSP and grant 01GM1907A to Treat ION), European Commission (EU grant 947588 to the ERN-RND registry and JPND grant 01ED16028 to ESMI) and is a member of the European Reference Network for Rare Neurological Diseases (Project No 739510). He served as advisor for Alexion, Novartis and Vico. He participates as a principal investigator in clinical studies sponsored by Vigil Neuroscience (VGL101-01.001; VGL101-01.002), Vico Therapeutics (VO659-CT01), PTC Therapeutics (PTC743-NEU-003-FA) and Stealth BioTherapeutics (SPIMD-301). All disclosures are unrelated to the present manuscript.
